BMS-202

BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity[1][2].

Product Specifications

CAS Number

[1675203-84-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; PD-1/PD-L1

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BMS-202.html

Purity

99.48

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CC(NCCNCC1=CC=C(OCC2=C(C)C(C3=CC=CC=C3)=CC=C2)N=C1OC)=O

Molecular Formula

C25H29N3O3

Molecular Weight

419.52

Precautions

H302, H315, H319, H335

References & Citations

[1]Zak KM, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) . Oncotarget. 2016 May 24;7 (21) :30323-35.|[2]Ashizawa T, et al. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomed Res. 2019;40 (6) :243-250.